ARTICLE | Clinical News
Iressa (ZD1839): Began Phase III trial enrollment
August 20, 2001 7:00 AM UTC
AstraZeneca plc (AZN), London, U.K. Product: Iressa ( ZD1839) Business: Cancer Therapeutic category: Signal transduction, Receptor antagonist Target: EGFR kinase Description: Oral inhibitor of the ...